NCT00824785终止3 期
REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 574
- 试验地点
- 6
- 主要终点
- Overall survival
研究概览
简要总结
To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients with advanced stomach and oesophageal cancer.
详细描述
Multicentre phase III, open labelled, randomised controlled trial. Randomisation will be 1:1 Arm A EOX and Arm B EOX + panitumumab. There will be a pilot phase II study of which the first 200 patients will be randomised and the primary endpoint for interim analysis will be when these patients have completed 6 months follow-up
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically verified inoperable locally advanced or metastatic adenocarcinoma or undifferentiated carcinoma of the oesophagus, oesophago-gastric junction, or stomach.
- •Slides of tumour tissue should be available for centralised EGFR staining
- •Uni-dimensionally measurable disease (CT or MRI as per RECIST).
- •No prior chemotherapy including previous adjuvant chemotherapy
- •No prior radiotherapy including adjuvant radiotherapy. Patients receiving palliative radiotherapy to sites of disease that are not measurable may be eligible and should be discussed with the Chief Investigator.
- •Male/female patients aged ≥18 years.
- •WHO Performance status 0, 1 or
- •Patients should have a projected life expectancy of at least 3 months.
- •Completion of baseline quality of life questionnaire (EORTC QLQ C30).
- •Adequate cardiac function; formal measurement of left ventricular ejection fraction is only required if clinically indicated.
- •Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5x109/l; white blood cell count ≥ 3x109/l; platelets ≥ 100x109/l; haemoglobin (Hb) ≥ 9g/dl (can be post-transfusion).
- •Adequate renal function: calculated creatinine clearance ≥50ml/minute.
- •Adequate liver function: serum bilirubin ≤1.5x ULN; ALT/AST ≤2.5x ULN; ALP ≤3x ULN (in the absence of liver metastases). If liver metastases are present, serum transaminases ≤5x ULN are permitted.
- •Written informed consent must be obtained from the patient before any study-specific procedures are performed (see Section 12.0).
- •Note: Epidermal growth factor receptor (EGFR) positivity by immunohistochemistry will not be required for study entry. Slides obtained from previously collected paraffin embedded archived specimens will be collected centrally for EGFR staining. A multivariate analysis will then be performed to exclude any effects of EGFR status on outcome measures
排除标准
- •Tumours of squamous histology.
- •Patients with locally advanced oesophageal cancer suitable for definitive chemoradiotherapy.
- •Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease.
- •Previous chemotherapy or radiotherapy. See Inclusion criteria for note regarding palliative radiotherapy.
- •Any major surgery within 4 weeks prior to the start of study treatment.
- •Any prior treatment with an EGFR signal transduction directed therapy.
- •Treatment with non-permitted medication.
- •Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, uncontrolled cardiac dysrhythmia, or myocardial infarction within the last 12 months. Patients with any history of clinically significant cardiac failure are excluded from study entry.
- •History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.
- •Known peripheral neuropathy >Grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible).
- •Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication (administration of capecitabine by naso-gastric or jejunostomy feeding tube is permitted).
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •Known hypersensitivity to panitumumab, components of the EOX regimen, or any of the constituents of these agents.
- •Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic active hepatitis B infection.
- •Other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial.
- •Female patients who may be pregnant or breastfeeding. Potential female patients of childbearing potential must have a negative pregnancy test within 7 days prior to randomisation, or have had amenorrhea for more than 2 years.
- •Patients of child-bearing potential not consenting to use adequate contraceptive precautions or abstinence during the course of the study and for 6 months after the last study drug administration for females, and 1 month for males.
- •Any other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
- •Treatment with another investigational agent within 30 days of commencing study treatment.
研究组 & 干预措施
Arm A EOX
Active Comparator
EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
干预措施: epirubicin, oxaliplatin, capecitabine (EOX) (Drug)
Arm B EOX + panitumumab.
Active Comparator
EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
干预措施: EOX + panitumumab (Drug)
结局指标
主要结局
Overall survival
时间窗: Early termination
Study closed early due to lack of efficacy
次要结局
- response rate, toxicity, quality of life and PFS(Early termination)
研究者
Professor David Cunningham
Head GI & Lymphoma Units
Royal Marsden NHS Foundation Trust
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerAdvanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung CancerNCT02163733AstraZeneca38
进行中（未招募）
3 期
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 DeletionNCT05338970Daiichi Sankyo586
终止
不适用
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR InhibitorsAnal, Colon, and Rectal CancersHead and Neck CancerColonic NeoplasmsColon/Rectal CancerColon/Rectal Cancer Colon CancerColon/Rectal Cancer Rectal CancerLung CancerColon CancerColon/Rectal Cancer Anal CancerHead and Neck CancersHead and Neck Cancers LipHead and Neck Cancers Oral CavityHead and Neck Cancers NasopharynxHead and Neck Cancers OropharynxHead and Neck Cancers HypopharynxHead and Neck Cancers LarynxHead and Neck Cancers TracheaLung Cancer Non-Small Cell Cancer (NSCLC)Lung Cancer Small Cell Lung Cancer (SCLC)Colorectal NeoplasmsNCT01137162Stanford University10
Unknown
2 期
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaSquamous Cell CarcinomaNCT01232374Biotech Pharmaceutical Co., Ltd.144
已完成
2 期
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor TherapyEGFR Inhibitor-Induced Skin RashNCT04239846TWi Biotechnology, Inc.74